Frankfurt
23.12.24
15:29 Uhr
6,250 Euro
-0,600
-8,76 %
-8,76 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.12. | Fortress Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.11. | Fortress Biotech GAAP EPS of -$0.76 misses by $0.17, revenue of $14.62M | 11 | Seeking Alpha | ||
| FORTRESS BIOTECH INC PREF Aktie jetzt für 0€ handeln | |||||
| 14.11. | Fortress Biotech, Inc.: Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights | 97 | GlobeNewswire (Europe) | Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally... ► Artikel lesen | |
| 14.11. | Fortress Biotech, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 14.11. | Fortress Biotech, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.11. | Fortress Biotech, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 27.09. | Fortress Biotech files to sell 6.19M shares of common stock for holders | 14 | Seeking Alpha | ||
| 27.09. | Fortress Biotech, Inc. - S-1, General form for registration of securities | 2 | SEC Filings | ||
| 26.09. | Hedge Fund and Insider Trading News: Chris Hansen, David Tepper, Paul Singer, Steven Cohen, Platinum Asset Management, Elliott Investment Management, Millennium Management, Fortress Biotech Inc (FBIO), Crowdstrike Holdings Inc (CRWD), and More | 31 | Insider Monkey | ||
| 26.09. | Fortress Biotech, Inc.: Fortress Biotech to Participate in October 2024 Investor Conferences | 4 | GlobeNewswire (USA) | ||
| 23.09. | Fortress Biotech, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 20.09. | Why Fortress Biotech (FBIO) Stock Is Getting Hammered | 7 | Benzinga.com | ||
| 20.09. | Fortress Biotech to sell 3.9M shares at $1.65 in registered direct offering | 1 | Seeking Alpha | ||
| 20.09. | Fortress Biotech secures $8 million in stock sales | 1 | Investing.com | ||
| 20.09. | Fortress Biotech sichert sich 8 Millionen US-Dollar durch Aktienverkäufe | 6 | Investing.com Deutsch | ||
| 20.09. | Fortress Biotech, Inc.: Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements | 4 | GlobeNewswire (USA) | ||
| 09.09. | Fortress Biotech Pref A stock hits 52-week low at $6.06 | 3 | Investing.com | ||
| 04.09. | Fortress Biotech, Inc.: Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference | 1 | GlobeNewswire (USA) | ||
| 16.08. | Fortress Biotech stock hits 52-week low at $6.41 amid market shifts | 3 | Investing.com | ||
| 14.08. | Roth/MKM optimistic on Fortress Biotech shares ahead of key drug approvals | 5 | Investing.com |
Seite:
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STRYKER | 352,30 | +0,03 % | Boston Scientific, Stryker, UnitedHealth: Diese Aktien profitieren vom demografischen Wandel | Altwerden - idealerweise bei bester Gesundheit - wollen wir alle. Doch die zunehmende Überalterung der Bevölkerung hat zwei Seiten. Zum einen belastet sie das Gesundheits-, Pflege- und Rentensystem... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 685,60 | -0,20 % | Sanofi and Regeneron's Dupixent, Leo Pharma's Anzupgo could help close treatment gap in chronic hand eczema: GlobalData | ||
| INTELLIA THERAPEUTICS | 11,700 | +0,60 % | Peering Into Intellia Therapeutics' Recent Short Interest | ||
| VIKING THERAPEUTICS | 40,730 | +0,17 % | AKTIEN IM FOKUS: Novo Nordisk sacken nach Daten ab - Gerresheimer schwach | KOPENHAGEN/FRANKFURT/NEW YORK (dpa-AFX) - Enttäuschende Studienergebnisse haben dem dänischen Pharmakonzern Novo Nordisk am Freitag den höchsten Kursverlust in seiner Geschichte eingebrockt. Die Papiere... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,498 | +6,87 % | PTA-News: Small- & MicroCap Investment: Initiating Coverage: Fundamental Research sieht NurExone-Kursziel bei 2,61 CAD? | DJ PTA-News: Small- & MicroCap Investment: Initiating Coverage: Fundamental Research sieht NurExone-Kursziel bei 2,61 CAD?
Unternehmensmitteilung für den Kapitalmarkt
Frankfurt (pta/22.12.2024/08:30)... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,829 | -1,15 % | Pacific Biosciences Of California, Inc. Q3 Loss Decreases, Beats Estimates | WASHINGTON (dpa-AFX) - Pacific Biosciences of California, Inc. (PACB) reported Loss for third quarter that decreased from the same period last year and beat the Street estimates.The company's... ► Artikel lesen | |
| GINKGO BIOWORKS | 8,950 | -1,65 % | Ginkgo Bioworks Reports Third Quarter 2024 Financial Results | Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions
Ginkgo... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 7,072 | -1,31 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | SAN CARLOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,270 | 0,00 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 1,020 | -2,21 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY, in a Phase 1 Study in Patients with Solid Tumors | SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced... ► Artikel lesen | |
| TERNS PHARMACEUTICALS | 5,600 | -1,75 % | Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia | Compelling molecular responses starting at lowest dose level in heavily pre-treated patients with high baseline BCR-ABL transcript levels Encouraging safety profile with no dose limiting toxicities... ► Artikel lesen | |
| BIOMEA FUSION | 4,020 | 0,00 % | Biomea Fusion, Inc. - 8-K, Current Report |
FORTRESS BIOTECH INC PREF gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 6,250 Euro und damit -8,76 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FORTRESS BIOTECH INC PREF finden Sie auf Wallstreet Online.
